development and commercial milestones, as well as tiered royalties on net sales. Lilly has been a long-time backer of ...

Eli Lilly (LLY) stock in focus as the company launches Mounjaro Kwikpen in India, intensifying competition with Novo ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's ...

Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance ...

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

This agreement grants Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize long-acting incretin products for cardiometabolic health, using Camurus’ proprietary ...

Sales of Eli Lilly’s (NYSE: LLY) Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the country following its commercial ...